Introduction
Malignant otitis externa (MOE), also known as skull base osteomyelitis or necrotising otitis externa, is a rare invasive form of external otitis, characterised by progressive spread of infection from the external auditory canal to involve the temporal bone and skull base, with gradual bone destruction. Prior to the availability of antibiotics, it was associated with mortality rates of up to 50%. 1 Outcomes have improved considerably with advances in antimicrobial therapy. Antibiotics are now considered an effective mainstay of treatment and surgery is reserved mostly for the purposes of biopsy and occasionally local debridement.
Pseudomonas aeruginosa is known to be the most common causative agent in MOE; 2, 3 however, other pathogens have been isolated, including fungal organisms. Pseudomonas is a Gram-negative bacterium not usually found in the eternal auditory canal, which is pathogenic only in the absence of normal host defences. 3 Consequently, MOE occurs primarily in immunocompromised individuals, particularly the elderly and persons with diabetes. 3, 4 Diabetes is almost ubiquitous in MOE, with a prevalence commonly cited as 90-100% of patients. [1] [2] [3] Various hypotheses have been made for this predisposition to MOE in persons with diabetes; two commonly cited are microangiopathy of the ear canal 1, 5 and the increased pH of cerumen in persons with diabetes. 6 Diabetes is particularly highly prevalent in the Australian Aboriginal population. In the most recent Australian Aboriginal and Torres Strait Islander (ATSI) Health Survey (2012-2013), one-in-six (18%) ATSI people aged 25 years and over had diabetes or high sugar levels, with rates ranging from 5% of ATSI people aged 25-34 years to 39% of those aged 55 years and over. The ATSI population was more than three times more likely to have diabetes than non-Aboriginal Australians. 7 Despite the high prevalence of a key risk factor in the ATSI population, there is a notable scarcity of literature on the topic of MOE in Australia. Only one published case series has been conducted to date, with 24 patients in an urban setting. 8 There have been no previous studies on MOE in the ATSI population. 8 The Royal Darwin Hospital, where the current study was conducted, is a tertiary referral hospital receiving all otolaryngology referrals in the state of Northern Territory of Australia. Despite an area of 1.35 million km 2 , the population density of the Northern Territory is 0.2 persons per square kilometre, with most of the population (>50%) living around the capital city of Darwin and the rest in rural or remote regions. Thirty-two per cent of the total population in the Northern Territory identify as ATSI, in contrast to national average (2.5%). The unique setting of this study provides the optimal conditions to explore the pattern of presentation, clinical course and outcomes in Australian Aboriginal patients; in particular, examining the link with diabetes in this population. The rurality and remoteness of some of the patients also provides a different perspective to the previous published case series, in terms of the challenges in managing a complex disease like MOE. 8 
Methods
A retrospective chart review of all adult patients (above 18 years old) presenting to Royal Darwin Hospital with acute otitis externa between January 2007 and October 2016 was performed. Patients with a diagnosis of MOE were included, but only if the diagnosis of MOE was confirmed by a combination of an otolaryngology clinical review, positive technetium bone scan study and positive microbiology cultures. Patients with a diagnosis of concurrent malignancy on biopsy were excluded from the study. The inclusion and exclusion criteria were chosen to capture a wider range of patients, while only including patients who had an accurate diagnosis of MOE.
Demographic data collected included age, sex, identification as Australian Aboriginal or Torres Strait Islander, urban or regional origin, as well as medical background, including diabetic status. The clinical course was monitored by length of hospitalisation, type and duration of antimicrobial therapy, disease resolution and complications. Disease resolution was defined by clinical history and examination, and where available, measured with progress gallium scans.
Variables are expressed as means and standard deviations (SDs) for continuous variables or as percentages for discrete variables. What is already known on this subject:
Ethics approval
• Malignant otitis externa is an aggressive infection of the skull base that has a mortality rate above 50% if untreated.
• Poorly controlled diabetes is a key risk factor for developing malignant otitis externa.
• No previous studies have explored the topic of malignant otitis externa, despite epidemic levels of diabetes in the Australian Aboriginal population.
What this study adds:
• In Australian Aboriginal patients with malignant otitis externa, there is a concerning tendency towards younger age at diagnosis, longer hospital stays and a significantly higher disease-specific mortality rate. There is also a higher-than-expected proportion of fungal malignant otitis externa.
• The rural and remote distribution of Australian Aboriginal patients in the Northern Territory provides significant challenges to the timely diagnosis and ongoing management of malignant otitis externa.
• Clinicians managing Australian Aboriginal patients with diabetes should have a high index of suspicion for malignant otitis externa and facilitate early referral, in the light of the findings of this study.
Results
A total of nine patients (n = 9) were diagnosed with MOE in the study period, based on the criteria described above. Of these, six (66%) were identified as Australian Aboriginal (none identified as Torres Strait Islander), who were all referred from regional centres. The mean age at diagnosis in the Australian Aboriginal patients was 54.2 AE 11.1 years, compared to 69.9 AE 8.3 years in the non-Australian Aboriginal group. Eight out of nine patients were men. All nine patients had diabetes, with an average glycated haemoglobin (HbA1c) of 8.4% on diagnosis. The average HbA1c for non-Australian Aboriginal patients and Australian Aboriginal patients was 9.0% and 7.7%, respectively.
Pseudomonas aeruginosa was the predominant causative organism, cultured in 55% of all patients. Other pathogens isolated within the Australian Aboriginal patients included a fungal organism, Scedosporium apiospermum complex, and multidrug resistant Staphylococcus aureus (Fig. 1) .
The average duration of hospital stay was considerably longer in the Australian Aboriginal patients compared to non-Australian Aboriginal patients (53.4 compared to 35.5 days, respectively; Table 1 ). Most patients were treated with a course of parenteral therapy of variable duration, followed by a course of oral therapy. Of the patients who received initial i.v. treatment, the length of therapy ranged between four and 12 weeks, with similar durations between the two groups (6.7 weeks; Table 1 ).
There was a wide variability in the duration of oral therapy, with patients receiving between 4 weeks and 1 year of therapy. The course of oral therapy, as well as total duration of treatment (combined i.v. and oral), tended however to be shorter in the Australian Aboriginal patients, with an average total duration of treatment of 17.17 weeks (SD, 12.27; range, 8-38) compared to 31 weeks (SD, 27.01; range, 4-58) in the non-Australian Aboriginal group. This trend remained after accounting for three Australian Aboriginal patients who died during the study period. This might be associated with the inherent difficulty in closely monitoring our Australian Aboriginal patients, who lived in remote communities.
Sixty-seven per cent of the Australian Aboriginal patients developed complications ( Table 2) . Two of the Australian Aboriginal patients died due to MOE (from progressive spread of the osteomyelitis along the skull base), resulting in a disease-specific mortality of 33%. One other Australian Aboriginal patient died of an unrelated viral illness within the study period. Of the remaining Australian Aboriginal patients who survived, two had complete resolution during the study period, while one had ongoing disease based on gallium scan but was lost to follow-up. In contrast to this, in the non-Australian Aboriginal group there were no deaths and all three patients had complete resolution. This is despite all three patients having some form of complication due to the severity of their MOE (jugular foramen syndrome, dural sinus thrombosis or facial nerve palsy). 5, 6, 8 The diabetes-related mortality rates are over eight times the rate for other Australians. 9 A significant contributor to the poor health status of Australian Aboriginal people is the poor access to health services, 10, 11 with barriers including poor availability of GPs, costs associated with travel, consultation fees, medicines, transport, lost wages and time taken to access care, distance and poor availability of services in remote areas. 11, 12 This is particularly true in the Northern Territory, where a small population of 250 000 is spread out over a large remote area equivalent to the size of France, Spain and Italy combined. According to the Australian Bureau of Statistics, about 25.5% of the population in the Northern Territory are mostly distributed in rural or remote regions.
Australian Aboriginal patients in our case series were affected at a younger age, had a higher diseasespecific mortality rate and had a longer duration of hospital stay. The younger age of Australian Aboriginal MOE patients likely reflects the earlier onset of diabetes and high diabetes prevalence in the ATSI population. Interestingly, in our current series, diabetes control, as reflected by the HbA1c levels on presentation, was better in our Australian Aboriginal patients. The higher mortality rate and longer duration of hospital stay, in our experience, is hence likely due to barriers associated with the remoteness of these patients. As described previously, all the Australian Aboriginal patients in this case series lived in rural or remote areas, often accessible only by flight, making the arrangement of posthospital care and follow up much more complex.
Surprisingly, there was a high prevalence of fungal MOE in Australian Aboriginal patients in this case series, with 33% of patients being culture-positive for the fungal organism S. apiospermum complex. Typically, fungal pathogens are more common in immunocompromised patients without diabetes and the most commonly isolated organism is Aspergillus fumigatus.
In this case series, all Australian Aboriginal patients were from regional or remote areas, which impacted their access to tertiary health care facilities. Over half of the patients did not have follow up gallium scans and another was lost to follow up after the initial progress scans showed residual uptake. This is highly relevant as gallium scans are widely accepted as the gold standard imaging modality for resolution of MOE; while computed tomography and magnetic resonance imaging might be diagnostic, they are less useful for follow up as the pathological changes visible on these scans persist beyond resolution of disease. 3 The lack of outpatient parenteral therapy services in the rural and remote areas, where a large proportion of the Australian Aboriginal MOE patients live, result in prolonged periods of hospitalisation and delayed discharge from hospital. This causes further lost income, social isolation and separation from the community.
Limitations
The power of this study is limited by its small sample size and retrospective nature. This was constrained by the small population of the region sampled and the rarity of this disease. In this case, we have only included patients who have been thoroughly proven to have MOE with clinical, radiological and microbiological evidence to eliminate inaccuracies in diagnosis. It is difficult to elucidate the true incidence and extent of MOE in the rural and regional communities, given the barriers in diagnosing and treating this disease. Given the high prevalence of diabetes and barriers to accessing medical care, it is entirely possible that the true incidence of MOE is much higher than average. Further research is needed to clarify this, particularly in the context of the evolving epidemic levels of diabetes in the Australian Aboriginal population.
Conclusion
Our study, keeping in mind the aforementioned limitations, demonstrates some concerning disparities in MOE outcomes in Australian Aboriginal patients, with tendency towards younger age at diagnosis, longer hospital stays and a higher disease-specific mortality rate. The rural and remote distribution of patients in the Northern Territory and in many areas of Australia remains a challenge to diagnosis and management of many conditions, and MOE is no exception. As well as improving access to both primary and tertiary care, an important factor in improving outcomes in this patient group is raising awareness of this rare disease. Primary care practitioners in regional and remote areas need to have a high index of suspicion of MOE in the Australian Aboriginal patient with diabetes and ensure prompt referral to specialist care.
